AUTHORS
Peter Grant Miller I, MD,PhD, Ygang Tang, PhD2, Ruxin Yang, MS3, David McKinney4, Mikolaj Slabicki5, Rishi Puram, MD, PhD6, Alexandra Gould, PhD7, Eugene Oh8
AFFILIATIONS
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
5 Massachusetts General Hospital, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Broad Institute of MIT & Harvard, Cambridge, Massachusetts, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
ABSTRACT
Background and Objective: Cytotoxic chemotherapy remains a foundational treatment for many cancers, yet its effectiveness is often constrained by intrinsic or acquired resistance and dose-limiting toxicities. Strategies that enhance the therapeutic index of chemotherapy could benefit a broad spectrum of cancer patients, most notably those with hematologic malignancies. The serine/threonine phosphatase PPM1D (WIP1) is a negative regulator of the DNA damage response (DDR) and p53 activation, and PPM1D is recurrently activated in myeloid malignancies through C-terminal truncating mutations. We and others have demonstrated that pharmacological inhibition or genetic loss of PPM1D sensitizes TP53-wild-type leukemia cells to DNA-damaging agents. Here, we report that this sensitization extends unexpectedly to TP53-mutant AML through a PPM1D- and p53-independent mechanism: direct inhibition of the drug efflux pump MDR1 (ABCB1). We further show that MDR1 is a ROS-driven, clinically relevant vulnerability in high-risk AML that can be overcome therapeutically.
Methods: We screened a panel of AML cell lines to determine whether PPM1D inhibition with GSK2830371, or additional compounds we generated, sensitized cells to different classes of chemotherapy. We performed multiplexed screens across hundreds of cancer cell lines using daunorubicin with or without GSK2830371. Follow-up studies used isogenic PPM1D-, TP53-, and MDR1-knockout models, structure-activity relationship (SAR) analysis of more than 50 PPM1D-inhibitor analogs, drug accumulation and MDR1 ATPase activity assays, and analysis of MDR1/ABCB1 expression across TCGA, BEAT-AML, Leucegene, and DepMap cohorts.
Results: GSK2830371 sensitized TP53-wild-type cells to most chemotherapeutic agents, but unexpectedly also sensitized TP53-mutant AML cells to daunorubicin and vincristine, and this effect persisted in PPM1D-knockout cells and was reproduced by non-PPM1D-inhibitory analogs, establishing PPM1D- and p53-independence. Biomarker association analysis across the multiplexed cell line screen linked sensitization directly to ABCB1/MDR1 expression, and isogenic MDR1-knockout cells confirmed the phenotype was MDR1-dependent: GSK2830371 and select analogs increased intracellular daunorubicin accumulation and altered MDR1 ATPase activity and efflux kinetics. SAR analysis identified a sulfonamide moiety that governs MDR1, but not PPM1D, engagement, enabling separation of the two activities. Across TCGA, BEAT-AML, and Leucegene patient cohorts, ABCB1/MDR1 expression was significantly elevated in TP53-mutant relative to TP53-wild-type AML, and this elevation was recapitulated in isogenic TP53-mutant cell lines and driven by a reactive oxygen species (ROS axis in which chemotherapy-induced ROS upregulated MDR1. Building on this, we defined three complementary strategies to overcome MDR1-high, TP53-mutant AML: (1) direct MDR1 inhibition via the dual-specificity PPM1D/MDR1 scaffold; (2) substitution of daunorubicin with the poor MDR1 substrate idarubicin; and (3) pharmacological exploitation of MDR1 efflux itself using the iron-chelating compound PAC-1 (GTPL5238), which selectively killed MDR1-high cells via an iron-dependent mechanism of action.
Conclusions: Our data establish MDR1 efflux as both a PPM1D/p53-independent chemosensitization target and a ROS-driven, biomarker-defined vulnerability that is heightened specifically in TP53-mutant AML. These findings provide a biological and therapeutic framework for inhibiting, bypassing, or exploiting MDR1-mediated resistance across TP53-wild-type and -mutant malignancies.
DISCLOSURES
Peter Grant Miller I, MD,PhD: No relevant conflicts of interest to declare.